Published in Parkinsonism Relat Disord on June 24, 2008
An ¹⁸F-FDG PET study of cervical muscle in parkinsonian anterocollis. J Neurol Sci (2014) 0.89
Clinical subtypes of anterocollis in parkinsonian syndromes. J Neurol Sci (2011) 0.80
Dropped head syndrome due to myogenic atrophy - a case report of surgical treatment. Diagn Pathol (2011) 0.79
Dropped Head Syndrome after Minor Trauma in a Patient with Levosulpiride-Aggravated Vascular Parkinsonism. J Mov Disord (2016) 0.75
No need to droop your head in Parkinson's disease? Parkinsonism Relat Disord (2009) 0.75
Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet (2009) 8.11
PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol (2010) 7.62
Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA (2006) 4.26
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol (2011) 3.36
Mitochondrial genome variation in eastern Asia and the peopling of Japan. Genome Res (2004) 3.34
Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann Neurol (2008) 2.95
p62/SQSTM1 cooperates with Parkin for perinuclear clustering of depolarized mitochondria. Genes Cells (2010) 2.91
PINK1-mediated phosphorylation of the Parkin ubiquitin-like domain primes mitochondrial translocation of Parkin and regulates mitophagy. Sci Rep (2012) 2.60
Diverse effects of pathogenic mutations of Parkin that catalyze multiple monoubiquitylation in vitro. J Biol Chem (2005) 2.60
PINK1 autophosphorylation upon membrane potential dissipation is essential for Parkin recruitment to damaged mitochondria. Nat Commun (2012) 2.55
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol Brain (2012) 2.18
LRRK2 regulates synaptic vesicle endocytosis. Exp Cell Res (2008) 2.09
Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity. Neuron (2007) 2.08
Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol (2008) 2.04
Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum Mol Genet (2004) 2.02
Parkinson's disease-associated kinase PINK1 regulates Miro protein level and axonal transport of mitochondria. PLoS Genet (2012) 2.01
Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain. EMBO Rep (2003) 2.01
Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol (2009) 2.00
Gradient echo T2*-weighted magnetic resonance imaging revealing cerebral microbleeds in a patient with microscopic polyangiitis complicated by cerebrovascular disease. J Stroke Cerebrovasc Dis (2011) 1.99
Parkin stabilizes PINK1 through direct interaction. Biochem Biophys Res Commun (2009) 1.89
Relationship of phosphorylated alpha-synuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies. Exp Neurol (2007) 1.89
Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum Mol Genet (2006) 1.83
Caffeine induces apoptosis by enhancement of autophagy via PI3K/Akt/mTOR/p70S6K inhibition. Autophagy (2011) 1.81
PINK1 is recruited to mitochondria with parkin and associates with LC3 in mitophagy. FEBS Lett (2010) 1.79
Novel PINK1 mutations in early-onset parkinsonism. Ann Neurol (2004) 1.72
Fabrication, characterization, and application of boron-doped diamond microelectrodes for in vivo dopamine detection. Anal Chem (2007) 1.67
Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann Neurol (2006) 1.66
Leucine-rich repeat kinase 2 associates with lipid rafts. Hum Mol Genet (2007) 1.65
A combinatorial code for the interaction of alpha-synuclein with membranes. J Biol Chem (2005) 1.60
A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain (2005) 1.57
Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol (2013) 1.56
Reversible cerebral vasoconstriction syndrome presenting as subarachnoid hemorrhage, reversible posterior leukoencephalopathy, and cerebral infarction. Intern Med (2011) 1.55
UCHL1 is a Parkinson's disease susceptibility gene. Ann Neurol (2004) 1.54
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol (2002) 1.54
Neuroprotective effect of recombinant human granulocyte colony-stimulating factor in transient focal ischemia of mice. J Cereb Blood Flow Metab (2006) 1.48
Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain. Stroke (2005) 1.47
Blepharospasm associated with multiple system atrophy: a case report and review of the literature. Parkinsonism Relat Disord (2004) 1.44
Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab (2011) 1.40
Siah-1 facilitates ubiquitination and degradation of synphilin-1. J Biol Chem (2003) 1.33
Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord (2007) 1.32
Multiplex families with multiple system atrophy. Arch Neurol (2007) 1.32
Pathogenesis of familial Parkinson's disease: new insights based on monogenic forms of Parkinson's disease. J Neurochem (2009) 1.27
A rotarod test for evaluation of motor skill learning. J Neurosci Methods (2010) 1.26
Pathogenetic mechanisms of parkin in Parkinson's disease. Lancet (2004) 1.25
Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome. J Biol Chem (2002) 1.25
Expanding the clinical phenotype of SNCA duplication carriers. Mov Disord (2009) 1.25
Ubiquitin, proteasome and parkin. Biochim Biophys Acta (2004) 1.25
p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain. Neurosci Lett (2006) 1.24
Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population. Neuroreport (2007) 1.23
Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. Mov Disord (2006) 1.20
14-3-3eta is a novel regulator of parkin ubiquitin ligase. EMBO J (2005) 1.18
Calbindin 1, fibroblast growth factor 20, and alpha-synuclein in sporadic Parkinson's disease. Hum Genet (2008) 1.14
Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion. Stroke (2006) 1.12
A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol (2009) 1.12
A collaborative study on the malignant syndrome in Parkinson's disease and related disorders. Parkinsonism Relat Disord (2003) 1.11
Mechanisms of genomic instabilities underlying two common fragile-site-associated loci, PARK2 and DMD, in germ cell and cancer cell lines. Am J Hum Genet (2010) 1.10
Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. Arch Neurol (2006) 1.09
Intrinsic and extrinsic erythropoietin enhances neuroprotection against ischemia and reperfusion injury in vitro. J Neurochem (2006) 1.08
Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J Neurosci (2004) 1.07
The fate of neural progenitor cells expressing astrocytic and radial glial markers in the postnatal rat dentate gyrus. Eur J Neurosci (2005) 1.07
Molecular pathogenesis of Parkinson's disease: update. J Neurol Neurosurg Psychiatry (2011) 1.07
Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations. Mov Disord (2006) 1.06
Parkinson's disease with and without REM sleep behaviour disorder: are there any clinical differences? Eur Neurol (2009) 1.06
Fibroblast growth factor 20 gene and Parkinson's disease in the Japanese population. Neuroreport (2007) 1.05
Analyses of the MAPT, PGRN, and C9orf72 mutations in Japanese patients with FTLD, PSP, and CBS. Parkinsonism Relat Disord (2012) 1.05
Diffusional kurtosis imaging of normal-appearing white matter in multiple sclerosis: preliminary clinical experience. Jpn J Radiol (2012) 1.05
Analysis of C9orf72 repeat expansion in 563 Japanese patients with amyotrophic lateral sclerosis. Neurobiol Aging (2012) 1.05
Autosomal recessive parkinsonism linked to parkin gene in a Tunisian family. Clinical, genetic and pathological study. Parkinsonism Relat Disord (2003) 1.05
Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease. Hum Gene Ther (2005) 1.05
Pilot study of H₂ therapy in Parkinson's disease: a randomized double-blind placebo-controlled trial. Mov Disord (2013) 1.04
Milestones in PD genetics. Mov Disord (2011) 1.04
Segmental zoster paresis of limbs: report of three cases and review of literature. Neurologist (2007) 1.03
Binding of laminin-1 to monosialoganglioside GM1 in lipid rafts is crucial for neurite outgrowth. J Cell Sci (2009) 1.03
Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1beta, and expression of caspase-11 in mice. J Biol Chem (2004) 1.03
Possibility for neurogenesis in substantia nigra of parkinsonian brain. Ann Neurol (2005) 1.03
Parkin and endoplasmic reticulum stress. Ann N Y Acad Sci (2003) 1.03